

Application No.: 10/071,962
Attorney Docket No.: TNX 98-03-01
Customer No.: 26839

CDR2: Ala Thr Ser Asn Leu Ala Ser (SEQ ID NO: 25), or

CDR3: Gln Gln Trp Thr Ser Asn Pro Phe Thr (SEQ ID NO: 26),

or the CDRs of the heavy chain variable region and the CDRs of the light chain variable region each include at least one of the amino acid sequences listed above for the respective heavy and light chains.

45. A composition comprising at least one agonist antibody according to claim 31 or 32, and a physiologically acceptable carrier, diluent, and/or excipient.
46. A method of treating a disease characterized by decreased neutrophil proliferation, comprising administering an effective amount of the agonist antibody of claim 31 to a patient in need of such treatment, wherein the antibody specifically binds to or interacts with human G-CSF receptor to stimulate neutrophil proliferation and differentiation.
47. The method of claim 46, wherein the disease is neutropenia. - -


REMARKS

Applicants, solely in an effort to expedite prosecution, cancel claims 1-30 and substitute claims 31-47, without disclaiming the subject matter of claims 1-30. Applicants reserve the right to file continuations and/or divisionals directed to the subject matter of these cancelled claims.

Applicants submit that Claims 31-47 are in condition for allowance and request a timely Notice of same.

Respectfully Submitted

Dated: April 24, 2003.

BY: 
Cheryl A. Liljestrand
Reg. No. 45,275